CD52 and mantle cell lymphoma: Therefore, subsequent experiments studied CD52 mAb therapy in combination with human serum as a source of complement only in REC-1 cells following 3 d ibrutinib pretreatment (consecutive setup) and included MAVER-1 as ibrutinib-resistant MCL cell line.